East Rutherford, New Jersey-based Cambrex Corporation has acquired Snapdragon Chemistry of Waltham, Massachusetts.
Snapdragon specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing automation technology and proprietary equipment to solve complex process and analytical development challenges.
Cambrex is a global contract development and manufacturing organization (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle.
The transaction is expected to close following the completion of customary regulatory approvals. This will be Cambrex’s second acquisition within a year along with Q1 Scientific, consistent with its strategy to expand its portfolio of specialized solutions for pharmaceutical development and manufacturing. Terms of the deal were not disclosed.
According to the LevinPro HC database, this was the 117th transaction in the Laboratories, MRI and Dialysis sector in 2022. This compares with 101 Laboratories, MRI and Dialysis deals reported between January 1, 2021, and November 21, 2021.
